Lipid-Based Nanocarriers for Topical Therapy of Cutaneous Leishmaniasis: An Insight into the Mechanism of Action

Amina Riaz1,2, Muhammad Farhan Ali Khan3, Aamir Jalil4

  • 1Department of Pharmacy, The Women University Multan, Multan 6000, Pakistan.

ACS Omega
|June 23, 2025
PubMed

Insights

Novel lipid-based nanocarriers offer a promising topical treatment for cutaneous leishmaniasis (CL), overcoming limitations of current therapies. These advanced formulations enhance drug delivery and efficacy for this widespread parasitic skin infection.

Area of Science:

  • Pharmacology and Drug Delivery
  • Dermatology
  • Parasitology

Background:

  • Cutaneous leishmaniasis (CL) is a significant global health concern caused by Leishmania parasites.
  • Existing CL treatments suffer from low efficacy, toxicity, and poor patient compliance.
  • There is a critical need for improved, patient-friendly topical therapies for CL.

Purpose of the Study:

  • To review the potential of lipid-based nanocarriers for topical treatment of CL.
  • To analyze the skin permeation mechanisms and targeting capabilities of these nanocarriers.
  • To provide a comprehensive overview of recent advances, challenges, and clinical prospects.

Main Methods:

  • Literature review focusing on lipid-based nanocarriers (liposomes, SLNs, NLCs) for CL.
  • Analysis of studies detailing formulation, drug delivery, and skin penetration.
  • Evaluation of targeting potential to skin and macrophage cells.

Main Results:

  • Lipid-based nanocarriers enhance bioavailability, stability, and efficacy of CL treatments.
  • These nanocarriers demonstrate potential for targeted delivery to infected skin sites.
  • Formulations like creams and gels offer convenient topical application.

Conclusions:

  • Lipid-based nanocarriers represent a promising strategy for effective and safe topical CL treatment.
  • Further research is needed to address formulation optimization, scalability, and long-term clinical efficacy.
  • Targeting strategies are crucial for maximizing therapeutic outcomes in CL lesions.

Related Concept Videos

Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
352
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160